Compare COIN & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | COIN | ILMN |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.0B | 37.0B |
| IPO Year | 2021 | 2000 |
| Metric | COIN | ILMN |
|---|---|---|
| Price | $145.36 | $237.02 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 38 | 21 |
| Target Price | $197.97 | ★ $261.60 |
| AVG Volume (30 Days) | ★ 6.4M | 2.4M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 170.87 |
| EPS | N/A | ★ 3.65 |
| Revenue | ★ $7,181,325,000.00 | $4,343,000,000.00 |
| Revenue This Year | N/A | $6.66 |
| Revenue Next Year | $26.28 | $6.89 |
| P/E Ratio | ★ N/A | $61.91 |
| Revenue Growth | ★ 9.40 | N/A |
| 52 Week Low | $135.46 | $112.65 |
| 52 Week High | $324.80 | $309.35 |
| Indicator | COIN | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 35.35 | 40.65 |
| Support Level | N/A | $188.51 |
| Resistance Level | $179.14 | $309.35 |
| Average True Range (ATR) | 8.88 | 14.82 |
| MACD | -3.30 | -6.24 |
| Stochastic Oscillator | 17.75 | 18.82 |
Founded in 2012, Coinbase is the leading cryptocurrency exchange platform in the United States. The company intends to be the safe and regulation-compliant point of entry for retail investors and institutions into the cryptocurrency economy. Users can establish an account directly with the firm, instead of using an intermediary, and many choose to allow Coinbase to act as a custodian for their cryptocurrency, giving the company breadth beyond that of a traditional financial exchange. While the company still generates the majority of its revenue from transaction fees charged to its retail customers, Coinbase uses internal investment and acquisitions to expand into adjacent businesses, such as prime brokerage and data analytics.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.